Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-013992

PRESIDENT AND CEO sold 5,000 shares at $16.49 ($82,453)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kintz Samuel PRESIDENT AND CEO 2025-05-19 Sale 10b5-1 −5,000 $16.49 $82,453 972,892 I: show line 1 in the form
Open-market sales · 5,000 sh · avg $16.49 · $82,453
Loading xslF345X05/form4-05212025_100549.xml…